- Suppliers
ADM 
Armor Pharma 
Asahi KASEI 
Ashland 
BASF 
Beneo 
Budenheim 
Captisol 
Clariant 
Croda 
DFE Pharma 
Excipio Chemicals 
Fuji Chemical 
Gattefossé 
Gangwal 
IamFluidics 
IOI Oleo 
Ingredient Pharm 
JRS Pharma 
Kerry 
KLK Oleo 
Lipoid 
Lubrizol Life Science Health 
MAGNESIA 
MEGGLE 
Nagase Viita 
Nordic Bioproducts 
Pfanstiehl 
pharm-a-spheres 
PMC Isochem 
Seppic 
ShinEtsu 
Sigachi 
SPI Pharma 
Südzucker 
Vikram Thermo 
Zerion Pharma 
All4Nutra
- Suppliers
ADM Armor Pharma Asahi KASEI Ashland BASF Beneo Budenheim Captisol Clariant Croda DFE Pharma Excipio Chemicals Fuji Chemical Gattefossé Gangwal IamFluidics IOI Oleo Ingredient Pharm JRS Pharma Kerry KLK Oleo Lipoid Lubrizol Life Science Health MAGNESIA MEGGLE Nagase Viita Nordic Bioproducts Pfanstiehl pharm-a-spheres PMC Isochem Seppic ShinEtsu Sigachi SPI Pharma Südzucker Vikram Thermo Zerion Pharma - All4Nutra
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations
Three critical aspects that define high concentration antibody products (HCAPs) are as follows: 1) formulation composition, 2) dosage form, and 3) primary packaging configuration. HCAPs have become successful in the therapeutic sector due to their unique advantage of allowing subcutaneous self-administration. Technical challenges, such as physical and chemical instability, viscosity, delivery volume limitations, and product immunogenicity, can hinder successful development and commercialization of HCAPs. Such challenges can be overcome by robust formulation and process development strategies, as well as rational selection of excipients and packaging components.
We compiled and analyzed data from US Food and Drug Administration-approved and marketed HCAPs that are ≥100 mg/mL to identify trends in formulation composition and quality target product profile. This review presents our findings and discusses novel formulation and processing technologies that enable the development of improved HCAPs at ≥200 mg/mL. The observed trends can be used as a guide for further advancements in the development of HCAPs as more complex antibody-based modalities enter biologics product development.
Table 1. List of excipients generally used in protein formulations and their functions
| Excipients | Function | Examples |
|---|---|---|
| Buffer | Maintain stable pH environment | Histidine, Phosphate, Acetate, Citrate, etc. |
| Sugar and polyol stabilizers | Conformational stabilizer for the antibody | Disaccharides – Sucrose, Trehalose, Maltose. Polyols – Sorbitol, Mannitol |
| Tonicity Agent | Maintain iso-tonicity | Sucrose, NaCl, Trehalose, Mannitol |
| Surfactant | Reduce interfacial stress | Polysorbate 20 and 80, Poloxamer 188 |
| Amino acid stabilizers | Stabilize the antibody by buffering or charge interactions or blocking hydrophobic interactions | Arginine, Proline, Glycine, Histidine, Methionine |
| Chelating agent | Prevent metal induced degradation | DTPA, EDTA |
| Viscosity Modifiers | Reduce solution viscosity | Arginine, Proline, Glycine, NaCl |
| Antioxidants | Inhibit oxidation | Methionine |
Download the full article as PDF here A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations
or read it here
Indrajit Ghosh, Hiten Gutka, Mary E. Krause, Ryan Clemens & Ramesh S. Kashi, A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations, Article: 2205540 | Received 11 Oct 2022, Accepted 18 Apr 2023, Published online: 27 May 2023, Download citation https://doi.org/10.1080/19420862.2023.2205540
Read more on Excipients for Parenterals here:
